Looksmax - Men's Self Improvement Forum

Welcome to the ultimate men’s self-improvement community where like-minded individuals come together to level up every aspect of their lives. Whether it’s building confidence, improving your mindset, optimizing health, or mastering aesthetics, this is the place to become the best version of yourself. Join the hood and start your transformation today.
  • Registrations are open to everyone for few days.

Mogs Soteraxfin (GTFIH) (1 Viewer)

Mogs Soteraxfin (GTFIH)

Biomaxx

Qui servat inopes
Joined
Oct 12, 2025
Posts
3,905
Reputation
8,816
I think ive came across a god made compound that I probably shoudnt be writing about

SRX-9147 (Soteraxifin): First-In-Class Osteo-Anabolic Mitogen

soreraxfin has just had its first published animal trail (rats)

Soteraxifin was administered 100mcg/kg to teenage rats and showed (imo) incredible results

Results showed- insane femur thickening and lengthening, large increase in bmd, near complete halt in chondrocytes differentiation (plate fusure) and slight myostatin inhibition (more lean muscle)

This compound was seen to work through 4 different main pathway

1.FGFR3 Pathway Inhibition
Unlike expensive antibody approaches, Soteraxfin is a small molecule FGFR3 inhibitor that penetrates the growth plate. Reduces constitutive STAT1 phosphorylation, allowing chondrocytes to stay proliferative longer. No impact on FGFR1/2/4 at therapeutic doses.

2. Wnt/β-Catenin Potentiation
Standard Wnt agonists hit LRP5/6 and wreck your gut. Soteraxfin amplifies endogenous Wnt signaling downstream at the Dvl/Axin level. Result: significant BMD accretion without the GI sides that killed other candidates in this class.

3. Myostatin Latency Maintenance
Binds the myostatin pro-domain with high affinity, preventing proteolytic activation. Serum active myostatin dropped 94% in the 100mcg cohort. Lean mass up 4.2kg in 8 weeks without training protocol changes.

4. CNP/NPR-B Signaling Amplification
Positive allosteric modulator at the NPR-B receptor. Endogenous CNP stays active 3-4x longer in growth plate tissue. cGMP elevation localized to bone - no systemic hypotension or vascular effects seen.

Results over a month-
Screenshot_20260401_143205_Kimi.jpg

These results are Unlike anything tested

Side Effects
Reportedly near to none
Mild headaches and early usage stool softening

⚠️⚠️⚠️⚠️ OPEN SPOILER​
April fools, silly mf 😘

birthdefect birthdefect Dexter Dexter Synapse Synapse Fr4mel3t Fr4mel3t carbon carbon tmpll tmpll FoidSlayer FoidSlayer XvideosDemon XvideosDemon
 
Joined
Mar 26, 2026
Posts
202
Reputation
358
I think ive came across a god made compound that I probably shoudnt be writing about

SRX-9147 (Soteraxifin): First-In-Class Osteo-Anabolic Mitogen

soreraxfin has just had its first published animal trail (rats)

Soteraxifin was administered 100mcg/kg to teenage rats and showed (imo) incredible results

Results showed- insane femur thickening and lengthening, large increase in bmd, near complete halt in chondrocytes differentiation (plate fusure) and slight myostatin inhibition (more lean muscle)

This compound was seen to work through 4 different main pathway

1.FGFR3 Pathway Inhibition
Unlike expensive antibody approaches, Soteraxfin is a small molecule FGFR3 inhibitor that penetrates the growth plate. Reduces constitutive STAT1 phosphorylation, allowing chondrocytes to stay proliferative longer. No impact on FGFR1/2/4 at therapeutic doses.

2. Wnt/β-Catenin Potentiation
Standard Wnt agonists hit LRP5/6 and wreck your gut. Soteraxfin amplifies endogenous Wnt signaling downstream at the Dvl/Axin level. Result: significant BMD accretion without the GI sides that killed other candidates in this class.

3. Myostatin Latency Maintenance
Binds the myostatin pro-domain with high affinity, preventing proteolytic activation. Serum active myostatin dropped 94% in the 100mcg cohort. Lean mass up 4.2kg in 8 weeks without training protocol changes.

4. CNP/NPR-B Signaling Amplification
Positive allosteric modulator at the NPR-B receptor. Endogenous CNP stays active 3-4x longer in growth plate tissue. cGMP elevation localized to bone - no systemic hypotension or vascular effects seen.

Results over a month-
View attachment 41457
These results are Unlike anything tested

Side Effects
Reportedly near to none
Mild headaches and early usage stool softening

⚠️⚠️⚠️⚠️ OPEN SPOILER​
April fools, silly mf 😘

birthdefect birthdefect Dexter Dexter Synapse Synapse Fr4mel3t Fr4mel3t carbon carbon tmpll tmpll FoidSlayer FoidSlayer XvideosDemon XvideosDemon
First high effort April fools thread I've seen, peak
 
Joined
Jan 7, 2026
Posts
1,078
Reputation
2,204
I think ive came across a god made compound that I probably shoudnt be writing about

SRX-9147 (Soteraxifin): First-In-Class Osteo-Anabolic Mitogen

soreraxfin has just had its first published animal trail (rats)

Soteraxifin was administered 100mcg/kg to teenage rats and showed (imo) incredible results

Results showed- insane femur thickening and lengthening, large increase in bmd, near complete halt in chondrocytes differentiation (plate fusure) and slight myostatin inhibition (more lean muscle)

This compound was seen to work through 4 different main pathway

1.FGFR3 Pathway Inhibition
Unlike expensive antibody approaches, Soteraxfin is a small molecule FGFR3 inhibitor that penetrates the growth plate. Reduces constitutive STAT1 phosphorylation, allowing chondrocytes to stay proliferative longer. No impact on FGFR1/2/4 at therapeutic doses.

2. Wnt/β-Catenin Potentiation
Standard Wnt agonists hit LRP5/6 and wreck your gut. Soteraxfin amplifies endogenous Wnt signaling downstream at the Dvl/Axin level. Result: significant BMD accretion without the GI sides that killed other candidates in this class.

3. Myostatin Latency Maintenance
Binds the myostatin pro-domain with high affinity, preventing proteolytic activation. Serum active myostatin dropped 94% in the 100mcg cohort. Lean mass up 4.2kg in 8 weeks without training protocol changes.

4. CNP/NPR-B Signaling Amplification
Positive allosteric modulator at the NPR-B receptor. Endogenous CNP stays active 3-4x longer in growth plate tissue. cGMP elevation localized to bone - no systemic hypotension or vascular effects seen.

Results over a month-
View attachment 41457
These results are Unlike anything tested

Side Effects
Reportedly near to none
Mild headaches and early usage stool softening

⚠️⚠️⚠️⚠️ OPEN SPOILER​
April fools, silly mf 😘

birthdefect birthdefect Dexter Dexter Synapse Synapse Fr4mel3t Fr4mel3t carbon carbon tmpll tmpll FoidSlayer FoidSlayer XvideosDemon XvideosDemon
How bored is bro 🤣
 

nineteen

save .gg
Joined
Nov 20, 2025
Posts
4,204
Reputation
10,452
I think ive came across a god made compound that I probably shoudnt be writing about

SRX-9147 (Soteraxifin): First-In-Class Osteo-Anabolic Mitogen

soreraxfin has just had its first published animal trail (rats)

Soteraxifin was administered 100mcg/kg to teenage rats and showed (imo) incredible results

Results showed- insane femur thickening and lengthening, large increase in bmd, near complete halt in chondrocytes differentiation (plate fusure) and slight myostatin inhibition (more lean muscle)

This compound was seen to work through 4 different main pathway

1.FGFR3 Pathway Inhibition
Unlike expensive antibody approaches, Soteraxfin is a small molecule FGFR3 inhibitor that penetrates the growth plate. Reduces constitutive STAT1 phosphorylation, allowing chondrocytes to stay proliferative longer. No impact on FGFR1/2/4 at therapeutic doses.

2. Wnt/β-Catenin Potentiation
Standard Wnt agonists hit LRP5/6 and wreck your gut. Soteraxfin amplifies endogenous Wnt signaling downstream at the Dvl/Axin level. Result: significant BMD accretion without the GI sides that killed other candidates in this class.

3. Myostatin Latency Maintenance
Binds the myostatin pro-domain with high affinity, preventing proteolytic activation. Serum active myostatin dropped 94% in the 100mcg cohort. Lean mass up 4.2kg in 8 weeks without training protocol changes.

4. CNP/NPR-B Signaling Amplification
Positive allosteric modulator at the NPR-B receptor. Endogenous CNP stays active 3-4x longer in growth plate tissue. cGMP elevation localized to bone - no systemic hypotension or vascular effects seen.

Results over a month-
View attachment 41457
These results are Unlike anything tested

Side Effects
Reportedly near to none
Mild headaches and early usage stool softening

⚠️⚠️⚠️⚠️ OPEN SPOILER​
April fools, silly mf 😘

birthdefect birthdefect Dexter Dexter Synapse Synapse Fr4mel3t Fr4mel3t carbon carbon tmpll tmpll FoidSlayer FoidSlayer XvideosDemon XvideosDemon
wow

ok
 

MedSlayer

Former Subhuman
Joined
Mar 7, 2026
Posts
863
Reputation
1,903
I think ive came across a god made compound that I probably shoudnt be writing about

SRX-9147 (Soteraxifin): First-In-Class Osteo-Anabolic Mitogen

soreraxfin has just had its first published animal trail (rats)

Soteraxifin was administered 100mcg/kg to teenage rats and showed (imo) incredible results

Results showed- insane femur thickening and lengthening, large increase in bmd, near complete halt in chondrocytes differentiation (plate fusure) and slight myostatin inhibition (more lean muscle)

This compound was seen to work through 4 different main pathway

1.FGFR3 Pathway Inhibition
Unlike expensive antibody approaches, Soteraxfin is a small molecule FGFR3 inhibitor that penetrates the growth plate. Reduces constitutive STAT1 phosphorylation, allowing chondrocytes to stay proliferative longer. No impact on FGFR1/2/4 at therapeutic doses.

2. Wnt/β-Catenin Potentiation
Standard Wnt agonists hit LRP5/6 and wreck your gut. Soteraxfin amplifies endogenous Wnt signaling downstream at the Dvl/Axin level. Result: significant BMD accretion without the GI sides that killed other candidates in this class.

3. Myostatin Latency Maintenance
Binds the myostatin pro-domain with high affinity, preventing proteolytic activation. Serum active myostatin dropped 94% in the 100mcg cohort. Lean mass up 4.2kg in 8 weeks without training protocol changes.

4. CNP/NPR-B Signaling Amplification
Positive allosteric modulator at the NPR-B receptor. Endogenous CNP stays active 3-4x longer in growth plate tissue. cGMP elevation localized to bone - no systemic hypotension or vascular effects seen.

Results over a month-
View attachment 41457
These results are Unlike anything tested

Side Effects
Reportedly near to none
Mild headaches and early usage stool softening

⚠️⚠️⚠️⚠️ OPEN SPOILER​
April fools, silly mf 😘

birthdefect birthdefect Dexter Dexter Synapse Synapse Fr4mel3t Fr4mel3t carbon carbon tmpll tmpll FoidSlayer FoidSlayer XvideosDemon XvideosDemon
Water
 

birthdefect

pray to the purple powder
Joined
Jan 7, 2026
Posts
1,424
Reputation
2,431
I think ive came across a god made compound that I probably shoudnt be writing about

SRX-9147 (Soteraxifin): First-In-Class Osteo-Anabolic Mitogen

soreraxfin has just had its first published animal trail (rats)

Soteraxifin was administered 100mcg/kg to teenage rats and showed (imo) incredible results

Results showed- insane femur thickening and lengthening, large increase in bmd, near complete halt in chondrocytes differentiation (plate fusure) and slight myostatin inhibition (more lean muscle)

This compound was seen to work through 4 different main pathway

1.FGFR3 Pathway Inhibition
Unlike expensive antibody approaches, Soteraxfin is a small molecule FGFR3 inhibitor that penetrates the growth plate. Reduces constitutive STAT1 phosphorylation, allowing chondrocytes to stay proliferative longer. No impact on FGFR1/2/4 at therapeutic doses.

2. Wnt/β-Catenin Potentiation
Standard Wnt agonists hit LRP5/6 and wreck your gut. Soteraxfin amplifies endogenous Wnt signaling downstream at the Dvl/Axin level. Result: significant BMD accretion without the GI sides that killed other candidates in this class.

3. Myostatin Latency Maintenance
Binds the myostatin pro-domain with high affinity, preventing proteolytic activation. Serum active myostatin dropped 94% in the 100mcg cohort. Lean mass up 4.2kg in 8 weeks without training protocol changes.

4. CNP/NPR-B Signaling Amplification
Positive allosteric modulator at the NPR-B receptor. Endogenous CNP stays active 3-4x longer in growth plate tissue. cGMP elevation localized to bone - no systemic hypotension or vascular effects seen.

Results over a month-
View attachment 41457
These results are Unlike anything tested

Side Effects
Reportedly near to none
Mild headaches and early usage stool softening

⚠️⚠️⚠️⚠️ OPEN SPOILER​
April fools, silly mf 😘

birthdefect birthdefect Dexter Dexter Synapse Synapse Fr4mel3t Fr4mel3t carbon carbon tmpll tmpll FoidSlayer FoidSlayer XvideosDemon XvideosDemon
NIGGA YOU GOT ME EXCITED
i was reading through that getting more and more shocked
 

Users who are viewing this thread

shape1
shape2
shape3
shape4
shape5
shape6
Top